Table 1.
Potential NK cell checkpoint molecules in cancer.
| Targets | Monoclonal antibody | Expression distribution | Ligand | Signaling motif |
|---|---|---|---|---|
| KILLER CELL LECTIN-LIKE RECEPTOR FAMILY | ||||
| NKG2A | Monalizumab, IPH2201 | CD8+ T cells and NK cells | HLA-E | ITIM |
| KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR FAMILY | ||||
| KIR | IPH2101, 1-7F9, Lirilumab, and IPH4102 | CD4+, CD8+ T cells, NK cells | MHC class I molecules | ITIM/ITAM |
| IMMUNOGLOBULIN SUPERFAMILY | ||||
| TIGIT | MTIG7192A, OMP-313M32, and AB154 | CD4+, CD8+ T cells, NK cells | CD155, CD112, CD113 | ITIM/ITT |
| CD96 | – | CD4+, CD8+ T cells, NK cells | CD155 | ITIM/YXXM |
| LAG-3 | Sym022, BMS-986016, Relatlimab, IMP321, and Eftilagimod Alpha | CD4+, CD8+ T cells, NK cells, B cells, and dendritic cells | MHC class II molecules, Fibrinogen-like Protein 1 | KIEELE |
| TIM-3 | sym 023, TSR-022, LY3321367, BGB-A425, and MBG453 | CD4+, CD8+ T cells, dendritic cells, NK cells, and monocytes | Gal-9, phosphatidylserine, HMGB1, Ceacam-1 | Tyrosine |